Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/199553HOMOLOGOUS RECOMBINATION MECHANISM-MEDIATED SEQUENCE REPLACEMENT GENE EDITING METHOD, AND ELEMENT STRUCTURE THEREOF
WO 29.09.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/CN2022/082125 Applicant ANHUI AGRICULTRURAL UNIVERSITY Inventor XU, Yonghan
Provided are a homologous recombination mechanism-mediated precise sequence replacement gene editing method, and an element structure. The method comprises: (1) on the basis of the 300-400 bp DNA sequence of a target region, inserting or deleting a plurality of DNA fragments to form an MsDFID sequence, wherein the MsDFID sequence is simultaneously taken as a guide RNA and donor template, and is also known as an MsDFID guide and donor RNA; (2) linking clustered regularly interspaced short palindromic repeats, namely PCRISR, or a Cas9 guide RNA skeleton, or an Escherichia coli CRISPR-Cas3 palindromic repeat sequence to the 3' end of an MsDFID donor template, and the latter three sequences are all used as guide RNA skeletons; and (3) constructing a donor vector by means of using the above-mentioned fusion sequence, and transforming same into Escherichia coli, wherein the inserted or deleted DNA fragments contained in the donor site in the MsDFID donor template are replaced to a corresponding site of the target region.
2.WO/2022/200858TARGETING ONCOGENTIC MUTATIONS WITH DUAL-CLEAVING ENDONUCLEASE
WO 29.09.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/IB2022/000155 Applicant SPECIFIC BIOLOGICS INC. Inventor STEAD, Brent, E.
Provided herein are compositions and methods of using chimeric nucleases comprising an I-TevI nuclease domain and a Cas domain for the targeting of oncogenes.
3.WO/2022/200633MICRORNA-27B INHIBITORS
WO 29.09.2022
Int.Class A61K 31/712
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
Appl.No PCT/EP2022/058142 Applicant NEUMIRNA THERAPEUTICS APS Inventor KAUPPINEN, Markus Sakari
The present invention provides antisense oligonucleotides complementary to miR-27b, capable of potently inhibiting the activity of miR-27b. Such compounds are useful as pharmaceuticals for treatment of diseases in the CNS or in the PNS including neurological diseases.
4.WO/2022/204443EFFICIENT TCR GENE EDITING IN T LYMPHOCYTES
WO 29.09.2022
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
Appl.No PCT/US2022/021820 Applicant GENENTECH, INC. Inventor RUTZ, Sascha
The present disclosure relates to engineered T cells and methods of making and using the same, as well as reagents for making the engineered T cells.
5.WO/2022/204023COMPOSITIONS AND METHODS FOR RAPID COVID-19 DETECTION
WO 29.09.2022
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
Appl.No PCT/US2022/021138 Applicant DUKE UNIVERSITY Inventor SONG, Xin
The present disclosure provides compositions and methods related to the detection of pathogenic organisms. In particular, the present disclosure provides compositions and methods related to the detection and/or quantification of viral RNA in a sample from a subject that has, or is suspected of having, a SARS-CoV-2 infection. Using rapid reverse-transcription loop-mediated isothermal amplification (RT-LAMP), the compositions and methods of the present disclosure provide a portable, inexpensive, rapid, and accurate assay platform for detecting and/or quantifying the presence of a pathogenic organism (e.g., SARS-CoV-2) in a patient sample.
6.WO/2022/202853EFFICACIOUS ANTI-CD26 ANTIBODY BIOMARKER
WO 29.09.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2022/013309 Applicant Y'S AC CO., LTD. Inventor MORIMOTO, Chikao
In the present invention, a potential prognostic biomarker for CD26-targeted therapy was identified based on phase I trial data of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors. Box-and-whisper plot analysis, scatter plot analysis, Pearson's product-moment correlation/Spearman's rank-order correlation, bar graph analysis and receiver operating characteristics (ROC) were used to examine the correlation between soluble CD26 titer variation with YS110 administration and tumor volume change, RECIST criteria evaluation and progression free survival (PFS). The mechanism for serum soluble CD26 titer variation was confirmed by in vitro experimentation. As a result, it was discovered, for the first time, that serum soluble CR26/DPP4 titer variation in the early stage of YS110 treatment is a predictive biomarker for evaluating thereapeutic effect.
7.20220307048ANTIMICROBIAL PEPTIDES
US 29.09.2022
Int.Class C12N 15/82
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
82for plant cells
Appl.No 17700591 Applicant Genvor Inc. Inventor Jesse Michael Jaynes

The present invention includes an antimicrobial peptide consisting of, consisting essentially of, or comprising, at least one of SEQ ID NO:1-20, nucleic acids encoding the peptides, methods for using the antimicrobial peptide generating plants which express the peptides sufficient to endow the plants with resistance to pathogenic bacteria and fungi, the use of the nucleic acids to produce peptides by cellular production such as fermentation or plant production systems of the antimicrobial peptide(s), and the use of the isolated antimicrobial peptide(s) in a spray or other mixture to treat plants to protect them from disease.

8.20220307046PLANT CELL MATRICES AND METHODS THEREOF
US 29.09.2022
Int.Class C12N 15/82
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
82for plant cells
Appl.No 17726141 Applicant Calyxt, Inc. Inventor Benjamin Campbell

Example embodiments in accordance with the present disclosure are directed to methods comprising contacting a plant part with a nucleotide sequence encoding a gene that induces plant cell matrix (PCM) formation, and culturing the plant part under growth conditions to enhance PCM formation.

9.20220308070MONITORING GENE THERAPY
US 29.09.2022
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No 17603935 Applicant LogicBio Therapeutics, Inc. Inventor B. Nelson Chau

The present disclosure provides, among other things, technologies for improving gene therapy. Among other things, the present disclosure provides technologies that permit monitoring and/or assessment one or more characteristics of a gene therapy treatment such as, for example, extent, level, and/or persistence of payload expression. In some embodiments, provided technologies particularly useful with integrating gene therapy.

10.20220305003METHODS OF TREATING CANCER WITH AN INHIBITOR OF ZNF827
US 29.09.2022
Int.Class A61K 31/4745
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
Appl.No 17616861 Applicant CHILDREN'S MEDICAL RESEARCH INSTITUTE Inventor Hilda PICKETT

The present disclosure relates to inhibitors of ZNF827 and their use alone or in combination with anti-cancer agents to treat cancer. Methods of selecting a subject for treatment with an inhibitor of ZNF827 are also detailed.